Health Trials

Mutations

1

Review clinical trials related to Mutations. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.

Participants needed: 68
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 15, 2026Locations: 1
Eligibility criteria

Age ≥ 18 years. [+8]

Participants who have received prior olutasidenib (Rezlidhiai, previously FT-210... [+10]

Read more